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Crohn’s disease (CD) is a chronic inflammation of the intestinalmucosa, characterized by periods of acute recurrence and remission.
Depending on the specific region affected, CD is classified as ileal CD or colonic CD. It is largely accepted that the intestinal
microbiota is involved in the onset of the pathology. Indeed, a reduced immune tolerance to components of the intestinal commensal
microbiota and inflammation of the intestinal barrier typifies patients with CD. Several studies have shown defective expression
of intestinal antimicrobial peptides (AMPs) in patients with CD compared to controls, particularly defensins. A reduction in 𝛼-
defensins is observed in ileal CD, while 𝛽-defensins are increased in colonic CD. In addition to an immunological basis, the disease
is frequently associated with genetic alterations includingmutations of NOD2 gene. Several therapeutic strategies to circumvent the
dysfunction observed in CD are currently under investigation.These include the use of delivery systems to administer endogenous
AMPs and the engineering of peptidomimetics that could ameliorate the severity of CD. In this review, the role defensins play in
CD and the strategies aimed at overcoming bacterial resistance will be discussed.
1. Introduction
Crohn’s disease (CD) is one of the principal types of inflam-
matory bowel disease (IBD) that can affect the intestinal
mucosa. Although the etiology of the disease is still unclear,
contributing factors include environmental elements, genetic
mutations, and pathogenic infections. In genetically predis-
posed individuals, these factors are responsible for an aggres-
sive and damaging immune response to microorganisms of
the intestinal microbiota. CD can attack any part of the
digestive tract, but in 50% of cases, it typically manifests in
the gastrointestinal tract and can be classified, based on the
specific region affected, as either ileal or colonic CD. Ileal CD
is restricted to the ileum and accounts for 30% of cases, while
colonic CD accounts for the remaining 20% of cases andmay
be particularly difficult to distinguish from ulcerative colitis
(UC) [1].
The lowest incidence rates for CD are found in Asia and
developing countries, with higher rates in theWesternWorld.
For example, the incidence of CD in Europe and North
America is approximately 3 per 100,000 people. In recent
decades, CD incidence has been relatively stable in the West,
whereas it is becoming more prevalent in Asia [2].
The role of innate immunity in CD became clear after
it was determined that NOD2/CARD15 (Nucleotide-Binding
Oligomerization Domain 2) was a susceptibility-associated
gene. NOD2/CARD15 acts as an intracellular sensor of
pathogen/microbe-associated molecular patterns (PAMPs or
MAMPs) [3, 4]. Recent studies have also identified a genetic
association between CD susceptibility and autophagy genes,
includingATG16L1 (Autophagy-Related 16-Like 1) and IRGM
(Immune-Related GTPase M) [5–7]. Genetic, immunologi-
cal, andmicrobial studies have shown that the etiology of IBD
involves a reduced tolerance to components of the intestinal
commensal microbiota [8]. Because of the large number of
enteric bacteria in contact with the intestinal mucosal surface
and the potential threat of opportunistic invasions, a perfect
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homeostasis is central for the maintenance of the intestinal-
microbial interface. This homeostasis is mediated by the
integrity of the intestinal barrier and a functional immunotol-
erance to intestinal microbiota and luminal antigens. NOD2,
the first gene identified for IBD susceptibility, represents an
example of a mechanism by which inflammatory disease
is propagated by a dysregulated response to the symbiotic
microbiota [3, 4, 9].The aim of this review is to discuss recent
developments on the general hypothesis that Crohn’s disease
is caused by a defect in the defensin-mediated antibacterial
mucosal barrier.
2. Microbiota in the Intestinal Mucosa and
Dysregulation in CD
The human intestinal microbiota is dominated by four bacte-
rial populations; about 90% belong to the phyla of Firmicutes
and Bacteroidetes, while the remainder is comprised of the
phyla of Proteobacteria (such as Escherichia and Helicobac-
ter), Actinobacteria, and numerous viruses, protists, and
fungi [10, 11]. Balance in the composition of gut microbiota
is critical for the health of the host. Indeed, the microbiota
contributes to a wide range of metabolic functions, including
development, immune response, and nutrition [12].
Some microbial hydrolytic enzymes produced by mem-
bers of the intestinal microbiota are important for the
fermentation of nondigestible dietary fiber (polysaccharides,
resistant starch, fibers of plant origin, and nondigestible
oligosaccharides) [13].The principal products of this fermen-
tation are hydrogen, carbon dioxide, and short-chain fatty
acids (SCFAs) such as butyrate and propionate [14]. SCFAs
are an important energy source for the host, with a central
role in lipogenesis and gluconeogenesis [15]. Moreover, they
also have an important anti-inflammatory function due to the
suppression of inflammatory cytokines [16].
The intestinal microbiota is therefore a key modulator
of the immune system. For example, gut microorganisms
play a role in the differentiation of different effector and
memory T cell populations and are necessary to produce
both proinflammatory (such as IL-17) and anti-inflammatory
molecules (such as IL-10) [17].
Dysregulation of the intestinal microbiota (“dysbiosis”)
has been reported in many patients with CD. For example,
decreased complexity in commensal bacterial profiles and
higher numbers of mucosa-associated bacteria have been
shown to be associated with CD development [18]. Metage-
nomic studies have also shown some differences in the
microbiomes of patients with CD and controls. The most
interesting conclusions from these studies are as follows: (i)
there is a quantitative decrease of several species of the Fir-
micutes and Bacteroidetes phyla in patients with CD. Among
the Bacteroidetes, Bacteroides fragilis (B. fragilis) has shown
important protective effects in mouse models of induced
colitis [19].Moreover, among the Firmicutes, a decrease in the
number of Faecalibacterium prausnitzii (F. prausnitzii) was
observed [20]. In mouse models of intestinal inflammation,
oral administration of F. prausnitzii reduced inflammatory
effects and helped to restore the normal microbiota compo-
sition [20]. Therefore, the decreased abundance of B. fragilis
and F. prausnitzii could contribute to the intestinal inflamma-
tory status in patients with CD; (ii) there is an increased level
of the Proteobacteria and Actinobacteria phyla, including
the family of Enterobacteriaceae, in patients with CD. In
particular, the amounts of adherent-invasive E. coli (AIEC)
were found to be higher in patients with lesions of the ileal
mucosa. Studies have demonstrated the ability of AIEC to
invade cells such as macrophages, replicate intracellularly,
and stimulate the release of large quantities of TNF (Tumor
Necrosis Factor), a proinflammatory factor [21, 22]; (iii) there
is an increase in the abundance of bacteria penetrating the
mucus layer in patients with CD. Some mucolytic bacteria
such as Ruminococcus gnavus and Ruminococcus torqueswere
observed in the intestinal epithelium of patients with CD.
Therefore, the microbiota may have closer contact with the
mucosa during CD [23].
3. Role of the Intestinal Membrane and Innate
Immune Response
The intestinal barrier plays an important role in the functions
of the immune system and although it allows the absorption
of ions, water, and other nutrients, it behaves as a barrier
to prevent the infiltration of bacteria through the mucosal
surface. A layer of columnar epithelial cells provides the first
line of defense againstmicroorganisms entering the intestinal
lumen.More than 80%of these cells are enterocytes, while the
remaining are enteroendocrine, goblet, or Paneth cells [24].
In many studies, it has been shown that there is a relationship
between variation in intestinal permeability and the status
of CD disease. Permeability was increased during acute CD
phases while it was decreased during remission phases [25,
26]. The increased intestinal permeability could also favour
bacterial translocation through the mucosa [27]. Moreover,
the intestinal epithelial surface is covered by a mucus layer
composed primarily of mucins, heavily glycosylated proteins
secreted by goblet cells. A thin anddiscontinuousmucus layer
in small intestine prevents direct contact of bacteria with the
epithelium and Peyer’s patches [28]. In the large intestine, the
mucus layer is dense and composed by an inner and outer
mucus layer [29]. The outer mucus layer contains a large
number of microbes and appears to be an amenable habitat
for commensal bacteria. However, the inner adherent mucus
layer contains a very low number of microbes and forms a
protective zone adjacent to the epithelial surface [30].The low
bacterial abundance in the inner layer is likely due to the pres-
ence of antimicrobial proteins (AMPs). These AMPs, which
are secreted by epithelial cells and retained in themucus layer,
promote bacterial killing by targeting the integrity of bacterial
cell walls [31]. Therefore, the action of some antibacterial
proteins (such as RegIII𝛾, defensins, and IgA) is important
in preventing direct contact between the epithelial layer and
microorganisms. The diffusion of undesired substances and
dysregulated synthesis of AMPs could result in decreased
protection and an increased permeability to bacteria in the
intestinal barrier.This would have consequent effects on local
inflammation [32, 33].
Changes in this process, which could contribute to
abnormal immune responses, have been observed in CD.
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For example, dysregulated IgA production has been demon-
strated in patients with CD. Normally, IgA immunoglobulins
are secreted by B cells in the intestinal lamina propria and
maintained in the mucus layer. The production of IgA is
regulated by dendritic cells that recognize bacteria present in
the intestinal epithelium.This allows B cells in Peyer’s patches
of the ileum to produce IgA specific for intestinal bacteria
[34]. Moreover, IgA regulates the composition and density
of intestinal commensal bacteria [35]. Conversely, in patients
with CD, IgA-mediated immune response is replaced by an
IgG-mediated response that has numerous effects on the local
microbiota [36].
Another immune defense mechanism against intracel-
lular pathogens is autophagy. Autophagy is the biological
process of cellular components degradation by lysosomal
vesicles derived from the endoplasmic reticulum. A recent
study found several polymorphisms in autophagy genes
implicated in CD disease: ATG16L1 (Autophagy-Related 16-
Like 1), IRGM (Immune-Related GTPase M), ULK1 (Unc-51
like autophagy activating kinase 1), PTPN2 (protein tyrosine
phosphatase nonreceptor type 2), and LRRK2 (leucine-rich
repeat kinase 2) [37]. Because NOD2 recruits and interacts
with ATG16L1, the presence of the ATG16L1 or NOD2 risk
variants could result in a defective response to pathogenic
species [38–40]. Patients with CD who are homozygous for
the ATG16L1 allele exhibit several structural abnormalities
in Paneth cells such as disorganized granule compartments,
fewer granules, and a lack of lysosomes in the ileal mucus
layer [39]. Paneth cells are specialized epithelial cells that
normally regulate the secretion of AMPs. A defect in the
autophagy process in patients with CD could lead to uncon-
trolled bacterial proliferation and may consequently cause
chronic inflammation.
4. Defensins: The Main Antimicrobial Proteins
Among the AMPs, there are peptides termed defensins
that are an important component of innate immunity. Ten
defensins have been identified in humans and classified
through structural differences into a family of six 𝛼-defensins
(HD) and a family of four 𝛽-defensins (HBD). The 𝛼-
defensins are primarily secreted by Paneth cells, neutrophils,
and certain macrophage populations of the small intestine.
𝛽-defensins are typically secreted by epithelial cells. Alpha-
defensins HD1-4 are also called human neutrophil peptides
(HNP) and participate in systemic innate immunity, while
HD5 andHD6 contribute to innate defense of the GImucosal
surface [41].
In the gastrointestinal tract, the function of these peptides
is to form micropores in bacterial membranes, causing an
efflux of ions and nutrients, loss of the structure, and eventual
cell collapse [41]. Human defensins represent themain family
of bacterial-membrane disrupting proteins and act through
several molecular mechanisms [42]. One of these mecha-
nisms includes the processing of inactive pro-𝛼-defensins by
trypsin in humans (matrix metalloproteinase 7 (MMP-7) in
mice). This enzyme induces a conformational change that
forms three sets of disulfide bonds between cysteine pairs
in the protein. Newly formed 𝛼-defensins form a dimeric
structure that produces a positively charged surface spatially
separated from hydrophobic regions, facilitating insertion
into negatively charged microbial membranes [43]. Other
mechanisms employed do not directly target and kill bacteria.
For example, HD6 oligomerizes forming long fibrils that
“capture” bacteria and prevent their passage through the
intestinal epithelium [44].
Defensins can also protect against pathogen colonization.
𝑀𝑀𝑃7−/− mice have strong susceptibility to oral administra-
tion of SalmonellaTyphimurium,whilemice that overexpress
HD5 show greater resistance than wild-type mice. This sug-
gests that 𝛼-defensins are fundamental for mucosal protec-
tion against intestinal bacterial pathogens [45, 46]. Moreover,
mice that that do not express 𝛼-defensins (𝑀𝑀𝑃7−/−) show
distinct differences in their intestinal microbiota compared
to mice that express 𝛼-defensins normally (wt). It is therefore
likely that defensins may regulate the composition and
density of bacterial communities in the digestive lumen [47].
5. Defensins: Regulation of
Expression, Secretion, and Activity in
the Small Intestine
The secretion and expression of epithelial defensins are con-
trolled by several transcriptional and posttranslationalmech-
anisms. The expression of some 𝛼-defensins and 𝛽-defensins
is regulated in a microbial-independent manner, through
the expression of proinflammatory cytokines including IL-
1𝛽 (HD5, HD6, or HBD1). They can also be regulated in a
bacterial-dependent way (HBD2) due to pattern recognition
receptors (PRRs) of the immune system [41, 48, 49].
Biosynthesis of defensins is activated by receptors that
recognize extracellular and intracellular bacterial compo-
nents. These include toll-like receptors (TLRs) and NOD2
receptors [50, 51]. After binding specific conserved micro-
bial molecules, TLRs activate pathway cascades that in
turn activate nuclear factor kB (NFkB). This promotes the
transcription of proinflammatory cytokines and AMPs [52].
Although the activation mechanism of NOD2 has not yet
been elucidated, some studies have shown that activation
is dependent on muramyl-dipeptide (MDP), a peptidogly-
can component that is present in both gram-positive and
gram-negative bacteria [53]. NOD2 receptors have important
roles in increasing the bactericidal activity of Paneth cells
and modulate the composition of the microbiota in the
small intestine [54]. Alpha-defensins are stored as inactive
propeptides within epithelial cell secretory granules and are
proteolytically processed by trypsin to produce mature active
proteins [55, 56]. The process of secretion is controlled by
bacterial signals. In the small intestine, these signals likely
originate from live bacteria or bacterial products such as
LPS and act directly on Paneth cells to induce degranulation.
Recent studies have suggested that Paneth cells also degran-
ulate in response to cytokines secreted by immune cells
[57]. Finally, proteins of the autophagy pathway also regulate
granule exocytosis in Paneth cells, as previously described.
The mechanisms regulating the synthesis of 𝛽-defensins
are still unclear. As to their activity, it has been demonstrated
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that HBD1 hasminimal antimicrobial activity in the presence
of oxidizing conditions. However, in the presence of a
reducing environment that mimics the conditions of the
intestinal lumen, there are conformational changes in HBD1
that allow it to elicit a potent antimicrobial activity [58].
6. Defensins and Crohn’s Disease
CD is characterized by a chronic inflammation that can affect
any part of the gastrointestinal tract, although the ileum
and colon are the regions most commonly affected. Research
into the mechanisms underlying this disease has found that
CD likely develops due to impaired antimicrobial activity of
the intestinal mucosa against components of the microbiota.
Commensal and potentially pathogenic bacteria can infiltrate
the intestinal epithelium, causing the chronic inflammation
that is typical of the disease. Reduced expression of defensins
was also found in patients with CD; ileal CD is characterized
by a decrease in the abundance of certain 𝛼-defensins, while
certain 𝛽-defensins are implicated in colonic CD. Among the
factors that contribute to impaired production of defensins
are mutations in the NOD2 gene, polymorphisms in the
promoters of defensin genes, and defects in theWnt pathway.
Because of the differences between ileal and colonic CD, it is
necessary to discuss them separately.
6.1. Defensins in Ileal Crohn’s Disease. Wehkamp et al. have
demonstrated that ileal CD is associated with a marked
decrease in HD5 and HD6 expression in Paneth cells, com-
pared to controls [59].This relative decrease in AMPs reduces
the antibacterial activity of the gut mucosa and consequently
allows the penetration of pathogenic bacteria [60].
The same researchers have also proposed an association
between the NOD2 receptor expressed in intestinal epithelial
cells and the regulation of 𝛼-defensin expression. Patients
with ileal CD and NOD2mutations show decreased amounts
of HD5 and HD6 mRNA in affected tissue, compared to
patients without similar mutations [61]. Depending on eth-
nicity, a variable percentage of patients affected by CD have
a mutation in the NOD2 gene [62]. Studies have shown that
threeNOD2 alleles are associated with ileal CD susceptibility,
the missense mutations Arg702Trp and Gly908Arg, and the
frameshift mutation Leu1007fsincC. Another outcome was
that the degree of inflammation was not associated with
reduced HD5 [63]. These results suggest that a loss-of-
function mutation in the CARD15 gene encoding NOD2 was
responsible for the reduced antimicrobial activity observed
at the mucosa [64]. However, some studies showed that
the NOD2 mutation alone may be not sufficient to explain
the HD5 decrease in IBD [65]. It has been proposed that
reduction of alpha-defensin expression is mainly due to loss
of surface epithelium as a consequence of inflammatory
changes. [65].
Another mechanism that may be involved in the reduced
levels of 𝛼-defensins in ileal CD is epithelial stem cell
differentiation meditated by Wnt signaling. There are two
distinct Wnt signaling mechanisms: the canonical and non-
canonical pathways. The canonical pathway does not require
the presence of 𝛽-catenin in order to be activated. The
noncanonical pathway is activated by 𝛽-catenin which, when
translocated into the nucleus of Paneth cells, interacts with T
cell Factor 4 (TCF4).This resulting 𝛽-catenin-TCF4 complex
binds to DNA in the nucleus, activating a suite of genes
that include the defensins [66]. Therefore, deficiency in
TCF4 is involved in the Paneth cell 𝛼-defensins reduction
[67]. Furthermore, polymorphisms in the gene encoding the
low-density lipoprotein receptor-related protein 6 (LRP6),
another component of the Wnt signaling pathway, has been
associated with ileal CD [68].Therefore, mutations in NOD2,
TCF4, and LRP6 could lead to decreased alpha-defensin pro-
duction and consequent inflammation. Interestingly, inade-
quateWnt ligand stimulation bymonocytes induces defective
Paneth cell-mediated innate immunity providing an addi-
tional mechanism in CD [69]. Because defects of Paneth cell
function may be reversed by Wnt ligands, this mechanism
was suggested as a potential therapeutic target for this disease
[69].
Finally, hypomorphic alleles of the gene encoding the X-
box-binding protein 1 (XBP1) are also associated with intesti-
nal inflammation. XBP1 is important for the development
of secretory cells and mice lacking XBP1 exhibit Paneth cell
dysfunction and associated intestinal inflammation [70].
6.2. Defensins in Colonic Crohn’s Disease. Unlike ileal CD,
the levels of 𝛼-defensins remain unchanged in colonic
CD, although significant differences in the expression of
𝛽-defensins are observed. While HBD1 is constitutively
expressed, HBD2 can be induced by both inflammatory
stimuli and signals derived from pathogenic or probiotic
bacteria, including Escherichia coli strain Nissle and certain
lactobacilli [71, 72].
Colonic CD is associated with increased secretion of
HBD2 but also low HBD1 levels [73]. In a noninflammatory
state, the expression of inducible 𝛽-defensins is low, but
expression is significantly increased during inflammation
generated in response to proinflammatory molecules, such
as IL-1 [74]. Wehkamp et al. have confirmed this by showing
that HBD2 is more abundant in patients with CD and UC
[75]. Moreover, there was increased expression of HBD2 in
inflamed tissues compared to noninflamed sites from the
samepatient [75, 76]. Twoother inducible𝛽-defensins,HBD3
and HBD4, were found to be only minimally expressed in
control patients and no significant changes in patients with
CDwere observed [77]. To explain the impaired expression of
some 𝛽-defensins that occurs in colonic CD, a decrease in 𝛽-
defensins copy number on chromosome 8 was hypothesized.
Fellermann et al. found significant differences between con-
trol groups and patients with CD; controls had a median of
four copies while colonic patients with CD had a median of
three [78].
In the intestine, HBD1 is partially under the control of the
nuclear receptor peroxisome proliferator activated receptor
𝛾 (PPAR-𝛾), an essential mediator of intestinal homeosta-
sis [79]. Abnormal PPAR-𝛾 production results in reduced
antimicrobial activity of the mucosa. Moreover, the single
nucleotide polymorphism (SNP) rs1800972 in the HBD1
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promoter was also shown to have a protective role in colonic
CDdevelopment and in other clinical contexts, including oral
infections and HIV infection. SNP rs1800972 is also involved
in the transcriptional expression of HBD3 [80–82].
7. Future Perspectives
Understanding the mechanisms underlying CD is necessary
for the future development of new therapies. There are now
new strategies that aim to reinforce intestinal barrier function
and restore the microbiota balance. E. coli strain Nissle
1917, Lactobacillus, and other known probiotics may have a
common feature of activating AMP induction.This may play
an important role in helping the mucosa prevent bacterial
invasion [71, 72]. The administration of endogenous AMPs
as novel therapeutic antibiotics also has potential but it is
necessary to first overcome some obstacles. These include
the fact that although AMPs do not readily induce bacterial
resistance, they have several specific properties (proteolytic
degradation by microbial and host enzymes, toxicity to
eukaryotic cell membranes) that make developing them into
therapeutics difficult [83, 84].
Several of these issues may be resolved through protein
engineering. For example, the creation of AMP variants
that are resistant to enzymatic digestion will allow the
killing of bacteria directly through interactions with bacterial
membranes [85]. Another strategy to improve the therapeutic
potential of AMPs may be the engineering of peptidomimet-
ics. These synthetic molecules mimic AMP structure but
are constructed with an altered number of charged amino
acids, reducing hydrophobicity and thus decreasing toxicity
to host cells [86]. Many of these peptidomimetics have
potent bactericidal activity against drug-resistant bacteria
[87]. To improve the delivery efficiency and reduce nonspe-
cific cytotoxicity, it may also be necessary to package natural
AMPs or peptidomimetics in carrier nanoparticles [88].With
these and other approaches, researchers are now working on
developing several new therapeutic molecules targeting CD.
8. Conclusions
AMPs, in particular defensins, are important for stabilizing
the composition of the intestinal microbiota. They perform
this action by preventing bacterial overgrowth and the inva-
sion of the epithelium by potentially pathogenic bacteria,
therefore facilitating normal function of the intestinal tract.
Aswe have outlined, alterations in expression of defensins
have negative effects on the microbiota and can cause
an inflammatory state. Defensin expression is intrinsically
altered in IBD and it may play a significant role in its
pathogenesis. In particular, ileal CD is associated with a lack
of Paneth cells, with a consequent reduction in HD5 and
HD6. Colonic CD is associated with a reduction in consti-
tutive HBD1 and an increase in inducible HBD2. Additional
genetic factors have also been identified, demonstrating
that most patients with CD have mutations in the NOD2
gene. Although these NOD2 mutations play a role in the
etiology of CD, several studies have demonstrated that they
alone are not sufficient for the development of the disease.
Restoring normal expression of AMPs may rebalance the
intestinal microbiota and ameliorate intestinal inflammation.
Therefore, future studies are needed to develop new strategies
to identify and administer potentially therapeutic molecules
to patients with CD.
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